tRNA-halves are prognostic biomarkers for patients with prostate cancer

Prostate cancer (CaP) is the second most common malignancy in men [1]. The diagnosis is based on digital rectal examination, prostate-specific antigen (PSA), prostate biopsy, and imaging modalities. Despite the efforts for accurate diagnosis, a high percentage of men diagnosed with CaP is overtreated with radical prostatectomy or radiotherapy [2,3]. On the other hand, a subset of patients with aggressive carcinoma faces the risk of CaP progression despite of treatment. Therefore, a biomarker allowing the identification of aggressive and indolent disease is required in order to improve the management of patients with CaP.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research